Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000246725 | SCV000319989 | likely pathogenic | Cardiovascular phenotype | 2015-09-04 | criteria provided, single submitter | clinical testing | The c.34442dupA variant, located in coding exon 131 of the TTN gene, results from a duplication of A at nucleotide position 34442, causing a translational frameshift with a predicted alternate stop codon (p.Y11482Vfs*6). This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6069 samples (12138 alleles) with coverage at this position. Truncating alterations in TTN have been observed at a significantly higher frequency among patients with dilated cardiomyopathy (DCM), or 54/203 (27%), compared to patients with hypertrophic cardiomyopathy (3 of 231, 1%, P=3x10-16) and healthy controls (7 of 249, 3%, P=9x10-14). Among families with multiple relatives with DCM, studies have also provided strong data demonstrating segregation of TTN truncations with disease (Herman DS et al. N Engl J Med. 2012;366(7):619-28; Pugh TJ et al. Genet Med. 2014;16(8):601-8). The functional mechanism of TTN truncations leading to cardiomyopathy is not well understood; however, frameshifts are typically deleterious in nature (ACMG Standards and guidelines for the interpretation of sequence variants. Genet Med. 2015;17(5):405-24). As such, the c.34442dupA variant is classified as likely pathogenic. |